Inhibition of cell transformation by sulindac sulfide is confined to specific oncogenic pathways
| Autor: | Manish Gala, Vincent W. Yang, Ronggai Sun |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2002 |
| Předmět: |
Cancer Research
Cell Antineoplastic Agents medicine.disease_cause Transfection Article Malignant transformation Mice Sulindac medicine Animals Oncogene Dose-Response Relationship Drug Chemistry 3T3 Cells digestive system diseases Genes src Kinetics medicine.anatomical_structure Cell Transformation Neoplastic Genes ras Oncology Mechanism of action Biochemistry v-Src Cancer research medicine.symptom Carcinogenesis Cell Division medicine.drug |
| Popis: | Non-steroidal anti-inflammatory drugs (NSAIDs) have been shown to reduce the risk of colorectal cancer (CRC). They are also known to induce the regression of colorectal adenomas, which are precursors to CRC. Despite these evidences, the exact mechanism by which NSAIDs exerts its anti-oncogenic effect is not completely understood. Using a focus formation assay, here we show that sulindac sulfide, a NSAID, specifically inhibits cell transformation mediated by oncogenic Ha-Ras, but not by other established oncogene products such as v-Src, G α 12, and G α 13. Our results suggest that the ability of sulindac sulfide to suppress transformation is confined to specific oncogenic pathways. Further studies of the sulindac-resistant oncogenic pathways may lead to identification of novel therapeutic agents that are effective in the prevention or treatment of CRC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|